D Edmund Anstey1, John N Booth2, Marwah Abdalla2, Tanya M Spruill2, Yuan-I Min2, Paul Muntner2, Daichi Shimbo2. 1. From the Department of Medicine, Columbia University Medical Center, New York, NY (D.E.A., M.A., D.S.); Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL (J.N.B., P.M.); Department of Population Health, New York University School of Medicine, New York, NY (T.M.S.); and School of Medicine, University of Mississippi Medical Center, Jackson, MS (Y.-I.M.). dea2123@cumc.columbia.edu. 2. From the Department of Medicine, Columbia University Medical Center, New York, NY (D.E.A., M.A., D.S.); Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL (J.N.B., P.M.); Department of Population Health, New York University School of Medicine, New York, NY (T.M.S.); and School of Medicine, University of Mississippi Medical Center, Jackson, MS (Y.-I.M.).
Abstract
BACKGROUND: Among individuals without hypertension based on clinic blood pressure (BP), it is unclear who should be screened for masked hypertension, defined as having hypertension based on out-of-clinic BP. We hypothesized that individuals with a higher 10-year predicted atherosclerotic cardiovascular disease (ASCVD) risk, calculated using the pooled cohort risk equations, have a higher prevalence of masked hypertension. METHODS AND RESULTS: We analyzed data from the Jackson Heart Study-a population-based cohort of blacks-to determine the association of predicted ASCVD risk with masked hypertension. The sample included 644 participants, 40 to 79 years of age, with clinic systolic/diastolic BP <140/90 mm Hg, who completed ambulatory BP monitoring, were free of cardiovascular disease, and had data on factors needed to calculate ASCVD risk. Ten-year predicted ASCVD risk was calculated using the pooled cohort risk equations. Any masked hypertension was defined as masked daytime hypertension (mean daytime systolic/diastolic BP ≥135/85 mm Hg), masked nighttime hypertension (mean nighttime systolic/diastolic BP ≥120/70 mm Hg), or masked 24-hour hypertension (mean 24-hour systolic/diastolic BP ≥130/80 mm Hg). The prevalence of any masked hypertension was 54.0%. Compared with participants in the lowest (<5%) predicted ASCVD risk category, multivariable-adjusted prevalence ratios (95% confidence interval) for any masked hypertension were 1.36 (1.03-1.79), 1.62 (1.22-2.16), and 1.91 (1.47-2.48) for those with ASCVD risk of 5% to <7.5%, 7.5% to <10%, and ≥10%, respectively. The C statistic for discriminating between participants with versus without any masked hypertension was 0.681 (95% confidence interval, 0.640-0.723) for ASCVD risk and 0.703 (95% confidence interval, 0.663-0.744) for clinic systolic BP and diastolic BP. CONCLUSIONS: Higher ASCVD risk was associated with an increased prevalence of masked hypertension. Although the discrimination of ASCVD risk for masked hypertension was not superior to clinic BP, risk prediction equations may be useful for identifying the subgroup of individuals with both masked hypertension and high predicted ASCVD risk.
BACKGROUND: Among individuals without hypertension based on clinic blood pressure (BP), it is unclear who should be screened for masked hypertension, defined as having hypertension based on out-of-clinic BP. We hypothesized that individuals with a higher 10-year predicted atherosclerotic cardiovascular disease (ASCVD) risk, calculated using the pooled cohort risk equations, have a higher prevalence of masked hypertension. METHODS AND RESULTS: We analyzed data from the Jackson Heart Study-a population-based cohort of blacks-to determine the association of predicted ASCVD risk with masked hypertension. The sample included 644 participants, 40 to 79 years of age, with clinic systolic/diastolic BP <140/90 mm Hg, who completed ambulatory BP monitoring, were free of cardiovascular disease, and had data on factors needed to calculate ASCVD risk. Ten-year predicted ASCVD risk was calculated using the pooled cohort risk equations. Any masked hypertension was defined as masked daytime hypertension (mean daytime systolic/diastolic BP ≥135/85 mm Hg), masked nighttime hypertension (mean nighttime systolic/diastolic BP ≥120/70 mm Hg), or masked 24-hour hypertension (mean 24-hour systolic/diastolic BP ≥130/80 mm Hg). The prevalence of any masked hypertension was 54.0%. Compared with participants in the lowest (<5%) predicted ASCVD risk category, multivariable-adjusted prevalence ratios (95% confidence interval) for any masked hypertension were 1.36 (1.03-1.79), 1.62 (1.22-2.16), and 1.91 (1.47-2.48) for those with ASCVD risk of 5% to <7.5%, 7.5% to <10%, and ≥10%, respectively. The C statistic for discriminating between participants with versus without any masked hypertension was 0.681 (95% confidence interval, 0.640-0.723) for ASCVD risk and 0.703 (95% confidence interval, 0.663-0.744) for clinic systolic BP and diastolic BP. CONCLUSIONS: Higher ASCVD risk was associated with an increased prevalence of masked hypertension. Although the discrimination of ASCVD risk for masked hypertension was not superior to clinic BP, risk prediction equations may be useful for identifying the subgroup of individuals with both masked hypertension and high predicted ASCVD risk.
Authors: Myra A Carpenter; Richard Crow; Michael Steffes; William Rock; Jeffrey Heilbraun; Gregory Evans; Thomas Skelton; Robert Jensen; Daniel Sarpong Journal: Am J Med Sci Date: 2004-09 Impact factor: 2.378
Authors: Rod Jackson; Carlene M M Lawes; Derrick A Bennett; Richard J Milne; Anthony Rodgers Journal: Lancet Date: 2005 Jan 29-Feb 4 Impact factor: 79.321
Authors: James G Wilson; Charles N Rotimi; Lynette Ekunwe; Charmaine D M Royal; Mary E Crump; Sharon B Wyatt; Michael W Steffes; Adebowale Adeyemo; Jie Zhou; Herman A Taylor; Cashell Jaquish Journal: Ethn Dis Date: 2005 Impact factor: 1.847
Authors: Herman A Taylor; James G Wilson; Daniel W Jones; Daniel F Sarpong; Asoka Srinivasan; Robert J Garrison; Cheryl Nelson; Sharon B Wyatt Journal: Ethn Dis Date: 2005 Impact factor: 1.847
Authors: Andrew S Levey; Lesley A Stevens; Christopher H Schmid; Yaping Lucy Zhang; Alejandro F Castro; Harold I Feldman; John W Kusek; Paul Eggers; Frederick Van Lente; Tom Greene; Josef Coresh Journal: Ann Intern Med Date: 2009-05-05 Impact factor: 25.391
Authors: Daniel N Pugliese; John N Booth; Luqin Deng; D Edmund Anstey; Natalie A Bello; Byron C Jaeger; James M Shikany; Donald Lloyd-Jones; Cora E Lewis; Joseph E Schwartz; Paul Muntner; Daichi Shimbo Journal: J Hypertens Date: 2019-12 Impact factor: 4.844
Authors: D Edmund Anstey; Daniel Pugliese; Marwah Abdalla; Natalie A Bello; Raymond Givens; Daichi Shimbo Journal: Curr Hypertens Rep Date: 2017-10-25 Impact factor: 5.369
Authors: Laura P Cohen; Demetria Hubbard; Calvin L Colvin; Byron C Jaeger; Bharat Poudel; Marwah Abdalla; Aisha T Langford; Shakia T Hardy; Mario Sims; Cora E Lewis; Paul Muntner; Daichi Shimbo Journal: Am J Hypertens Date: 2021-11-20 Impact factor: 3.080